Catalent Pharmaceutical Solutions, a wholly-owned subsidiary of Catalent Inc., has selected Durham as the site of a new facility that will employ 201 people. The new facility will focus on growing Catalent's bioanalytics business segment, with a focus on cell and gene therapies. The company plans to invest nearly $40 million by the end of 2026, according to the North Carolina Department of Commerce.
The company could receive more than $1 million in performance-based incentives from the state, along with an additional $530,000 in incentives, according to the terms of a deal with the state's Economic Investment Committee.
An economic model used by the state projects that the new facility in Durham could boost North Carolina’s gross domestic product by approximately $378 million and increase net state revenue by $8.3 million.